CMEducation Resources, LLC - publications, events, lectures
- Street address
- United States
- Founded at
- 2013-02-21
- Website
- CMEducation Resources, LLC
- Views
- 1250
- Description
- CMEducation Resources, LLC is a full-service provider of innovative, integrated, multi-platform CME programs that, every month, engage more than 160,000 unique physicians and allied healthcare professionals across multiple primary care and specialty-focused disease states. As one of the most creative, technologically-advanced medical education companies in the world, we offer a unique combination of scientifically rigorous, dynamic, and innovative CME programs that have garnered 34 eHealthcare Leadership Awards over the past three years.
Melding ultra-rigorous scientific content with meticulous compliance-adherence processes and quality reviews, CMEducation programs have an established track record producing attendance record-breaking symposia and summits, the impact of which is substantiated by measurable outcomes in the domains of performance improvement, guideline adherence, and knowledge acquisition.
For the past 10 years, CMEducation's activities have galvanized motivated learners—primary care physicians, clinical specialists, investigators and leading global authorities—around educational activities that optimize the quality and effectiveness of patient care at the front lines of clinical practice.
Shared content
Optimizing the Risk-Benefit Therapeutic Equation for...
Neurologic specialists and their patients understand that multiple sclerosis (MS) is a lifelong, immune-mediated progressive disorder. The early age of onset...
Optimizing the Risk-Benefit Therapeutic Equation for...
Neurologic specialists and their patients understand that multiple sclerosis (MS) is a lifelong, immune-mediated progressive disorder. The early age...
Minimizing Risks and Maximizing Efficacy for Management...
Multiple sclerosis (MS) affects nearly 400,000 people in the United States and over 2.5 million people worldwide. Diagnostic methods and treatment plans developed...
Optimizing the Risk-Benefit Therapeutic Equation for...
Neurologic specialists and their patients understand that multiple sclerosis (MS) is a lifelong, immune-mediated progressive disorder. The early age of onset...
Minimizing Risks and Maximizing Efficacy for Management...
Multiple sclerosis (MS) affects nearly 400,000 people in the United States and over 2.5 million people worldwide. Diagnostic methods and treatment plans developed...
Optimizing the Risk-Benefit Therapeutic Equation for...
Neurologic specialists and their patients understand that multiple sclerosis (MS) is a lifelong, immune-mediated progressive disorder. The early age of onset...
Minimizing Risks and Maximizing Efficacy for Management...
Multiple sclerosis (MS) affects nearly 400,000 people in the United States and over 2.5 million people worldwide. Diagnostic methods and treatment plans developed...
Minimizing Risks and Maximizing Efficacy for Management...
Multiple sclerosis (MS) affects nearly 400,000 people in the United States and over 2.5 million people worldwide. Diagnostic methods and treatment plans developed...
Optimizing the Risk-Benefit Therapeutic Equation for...
Neurologic specialists and their patients understand that multiple sclerosis (MS) is a lifelong, immune-mediated progressive disorder. The early age of onset...
Optimizing the Risk-Benefit Therapeutic Equation for...
Neurologic specialists and their patients understand that multiple sclerosis (MS) is a lifelong, immune-mediated progressive disorder. The early age of onset...
Minimizing Risks and Maximizing Efficacy for Management...
Multiple sclerosis (MS) affects nearly 400,000 people in the United States and over 2.5 million people worldwide. Diagnostic methods and treatment plans developed...
Optimizing the Risk-Benefit Therapeutic Equation for...
Neurologic specialists and their patients understand that multiple sclerosis (MS) is a lifelong, immune-mediated progressive disorder. The early age of onset...
Minimizing Risks and Maximizing Efficacy for Management...
Multiple sclerosis (MS) affects nearly 400,000 people in the United States and over 2.5 million people worldwide. Diagnostic methods and treatment plans developed...
Optimizing the Risk-Benefit Therapeutic Equation for...
Neurologic specialists and their patients understand that multiple sclerosis (MS) is a lifelong, immune-mediated progressive disorder. The early age of onset...
Minimizing Risks and Maximizing Efficacy for Management...
Multiple sclerosis (MS) affects nearly 400,000 people in the United States and over 2.5 million people worldwide. Diagnostic methods and treatment plans developed...
Minimizing Risks and Maximizing Efficacy for Management...
Multiple sclerosis (MS) affects nearly 400,000 people in the United States and over 2.5 million people worldwide. Diagnostic methods and treatment plans developed...
Optimizing the Risk-Benefit Therapeutic Equation for...
Neurologic specialists and their patients understand that multiple sclerosis (MS) is a lifelong, immune-mediated progressive disorder. The early age of onset...